About sunshine biopharma inc - SBFM
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.
SBFM At a Glance
Sunshine Biopharma, Inc.
333 Las Olas Way
Fort Lauderdale, Florida 33301
| Phone | 1-954-330-0684 | Revenue | 36.31M | |
| Industry | Pharmaceuticals: Major | Net Income | -5,975,352.00 | |
| Sector | Health Technology | 2025 Sales Growth | 4.105% | |
| Fiscal Year-end | 12 / 2026 | Employees | 50 | |
| View SEC Filings |
SBFM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.141 |
| Price to Book Ratio | 0.262 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.768 |
| Enterprise Value to Sales | -0.088 |
| Total Debt to Enterprise Value | -0.255 |
SBFM Efficiency
| Revenue/Employee | 726,117.82 |
| Income Per Employee | -119,507.04 |
| Receivables Turnover | 10.493 |
| Total Asset Turnover | 1.197 |
SBFM Liquidity
| Current Ratio | 4.167 |
| Quick Ratio | 2.077 |
| Cash Ratio | 1.416 |
SBFM Profitability
| Gross Margin | 32.842 |
| Operating Margin | -12.336 |
| Pretax Margin | -16.399 |
| Net Margin | -16.458 |
| Return on Assets | -19.708 |
| Return on Equity | -25.679 |
| Return on Total Capital | -25.053 |
| Return on Invested Capital | -24.959 |
SBFM Capital Structure
| Total Debt to Total Equity | 3.526 |
| Total Debt to Total Capital | 3.406 |
| Total Debt to Total Assets | 2.701 |
| Long-Term Debt to Equity | 2.592 |
| Long-Term Debt to Total Capital | 2.502 |